Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension and long-term observational study in patients previously enrolled in Genentech/Roche-sponsored atezolizumab studies
2016-005189-75Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in cancer, transitional cell carcinoma of the bladder (TCC), sponsored by Roche. Started Jun 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2016-005189-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005189-75.